Abstract: Provided herein are novel compounds, for example, compounds having a structure according to Formula III-1 to III-12, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting DGKs in a cell, and/or in treating various diseases such as cancer or viral infections.

Abstract: Systems and methods are directed to selecting and delivering targeted content. In response to a request from a user, a central control component accesses content delivery data and content provider settings. Based on the content delivery data and the content provider settings, the central control component generates content delivery settings that include a plurality of frequency capping (Fcap) rules. The content delivery settings are transmitted to a serving system. A determination component of the serving system accesses user data associated with the user that indicates user preferences. Based on the content delivery settings and the user data, the determination component selects a piece of content to deliver to the user. A delivery component then delivers the piece of content to the user.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula I, Formula II-1 to II-7, Formula III-1 to III-9, IV, or V, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting DGKa and/or DGKz in a cell, and/or in treating various diseases such as cancer or viral infections.

Abstract: The present invention discloses a compound represented by formula 1a or formula 1b, an optical isomer, prodrug or pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and their use in preparation of a CDK2 inhibitor

Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

Abstract: A display panel and a display device are provided. The display panel includes a pixel driving circuit, a scan line, and a light-emitting control line connected to the pixel driving circuit. The pixel driving circuit includes a driving transistor, a first reset module, and a light-emitting element. An output terminal of the first reset module is connected to a gate of the driving transistor and an output terminal of the driving transistor is electrically connected to the light-emitting element. An input terminal of the first reset module is connected to the scan line or the light-emitting control line. A scan signal provided by the scan line or a light-emitting control signal provided by the light-emitting control line is multiplexed as a first reset signal provided by the reset module to the gate of the driving transistor.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in treating cancer.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

Abstract: A display panel has a display region and a frame region outside the display region. The display region includes a plurality of pixel circuits. The display panel includes a base substrate, a buffer layer, a semiconductor layer, a power signal layer, and an auxiliary circuit layer. The buffer layer is on a side of the base substrate. The buffer layer includes an a-Si layer. The semiconductor layer is on a side of the buffer layer away from the base substrate. The power signal layer is on a side of the semiconductor layer away from the base substrate. The power signal layer includes a plurality of first power voltage lines in the display region, and one first power voltage line of the plurality of first power voltage lines are electrically connected to a corresponding pixel circuit.

Abstract: A display panel and a display device are provided. The display panel is divided into an active area and a non-active area. The non-active area is divided into a first area, a flexible area and a second area sequentially arranged towards the active area. The display panel includes a substrate, an array layer, a touch wiring and a first signal wiring. The touch wiring includes a first touch lead, a second touch lead and a third touch lead that are electrically connected. The first touch lead is at least partially arranged in the array layer on a side of a first via hole group away from the flexible area. This display panel is developed into an in-cell touch panel.

Abstract: Provided herein are solid dispersions and pharmaceutical compositions of Compound 1. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof the solid dispersions or compositions described herein.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable N salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting TYK2, and/or function of IL-12, IL-23 and/or INF-alpha, and/or in treating various associated diseases or disorders.

Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: A display panel, a method for driving the same, and a display apparatus are provided. The display panel includes a plurality of light-emitting elements. Each one of the light-emitting element is electrically connected to M pixel circuits, where M is a positive integer greater than or equal to 2. The M pixel circuits are configured to drive the light-emitting element to emit light respectively during different display phases of the display panel.

Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: The present disclosure provides a display panel, a method for driving the display panel, and a display apparatus. The display panel includes multiple pixel circuits. The pixel circuit includes a drive transistor and at least one switch unit. At least one switch unit includes M thin film transistors connected in parallel, and M is a positive integer greater than or equal to 2. The M thin film transistors are configured to be turned on during different display phases, respectively.

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.

Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.